Recurrence of Stroke in Patients with AF Using NOACs

  • Yasushi UenoEmail author


Objective: To evaluate the risk factors of recurrent thromboembolic cerebral infarction in patients with non-valvular atrial fibrillation (NVAF), who were treated with non-vitamin K antagonist oral anticoagulants (NOACs).

Methods: The data of patients is collected from the database of our institute for about 3 years (between 2013 April and 2015 December).

Results: We analyzed 16 patient’s data (14 male, 2 female, median age 67.0 years) in whom recurrent thromboembolic cerebral infarction occurred despite receiving NOACs. 14 of 16 patients with recurrent ischemic stroke received reduced dose drug, and in 10 of 14 patient with reduced dose drug, inappropriate dose setting (i.e., out of drug dose criteria of NOACs) has been selected by the physicians or practitioner concerning about the risk for intracranial hemorrhage and patient’s age. After we have changed to the appropriate dose, recurrence of thromboembolic cerebral infarction was not observed.

More than 70 % of recurrent cerebral infarction occurred in patients with inappropriate underdose use of NOACs.

Conclusions: This paper demonstrates that patients with inappropriate reduced dose selection of NOACs carry a significant risk of recurrent thromboembolic cerebral infarction despite treated with NOACs anticoagulation, highlighting the need for appropriate drug dose selection for stroke prevention in real-world NVAF patients.


Recurrent stroke NOAC Inappropriate dose setting 


  1. 1.
    Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Heart Study. Stroke 1991; 22:983–988.Google Scholar
  2. 2.
    Atrial Fibrillation Investigators. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Arch Intern Med 1994;154:1449–1457.Google Scholar
  3. 3.
    Hughes M, Lip GY. Stroke and thromboembolism in atrial fibrillation: a systematic review of stroke risk factors, risk stratification schema and cost effectiveness data. Thromb Haemost 2008;99:295–304.Google Scholar
  4. 4.
    Stroke in Atrial Fibrillation Working Group. Independent predictors of stroke in patients with atrial fibrillation: a systematic review. Neurology 2007;69:546–554.Google Scholar
  5. 5.
    Murphy NF, Simpson CR, Jhund PS, et al. A national survey of the prevalence, incidence, primary care burden and treatment of atrial fibrillation in Scotland. Heart. 2007;93:606–12.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Miyasaka Y, Barnes ME, Gersh BJ, et al. Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. Circulation. 2006;114:119–25.CrossRefPubMedGoogle Scholar
  7. 7.
    Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007;146:857–867.Google Scholar
  8. 8.
    Ogilvie IM, Newton N, Welner SA, et al. Underuse of oral anticoagulants in atrial fibrillation: a systemic review. Am J Med 2010;123:638–645.Google Scholar
  9. 9.
    Inoue H, Nozawa T, Okumura K, et al. Attitudes of Japanese cardiologists toward anticoagulation for nonvalvular atrial fibrillation and reasons for its underuse. Circ J. 2004;68:417–21.CrossRefPubMedGoogle Scholar
  10. 10.
    Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarinin patients with atrial fibrillation. N Engl J Med. 2009;361:1139–51.CrossRefPubMedGoogle Scholar
  11. 11.
    Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365:883–91.CrossRefPubMedGoogle Scholar
  12. 12.
    Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients withatrial fibrillation. N Engl J Med. 2011;365:981–92.CrossRefPubMedGoogle Scholar
  13. 13.
    Giugliano RP, Ruff CT, Braunwald E, et al. Once-daily edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013;369:2093–104.CrossRefPubMedGoogle Scholar
  14. 14.
    Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomized trials. Lancet. 2014;383:955–62.CrossRefPubMedGoogle Scholar
  15. 15.
    Skanes AC, Healey JS, JA C, et al. Focused 2012 update of the Canadian Cardiovascular Society atrial fibrillation guidelines: recommendations for stroke prevention and rate/ rhythm control. Can J Cardiol. 2012;28:125–36.CrossRefPubMedGoogle Scholar
  16. 16.
    Camm AJ, Lip GY, DeCaterina R, et al. 2012 Focused update of theESC Guidelines for the management of atrial fibrillation: an update of the2010ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J. 2012;33:2719–47.CrossRefPubMedGoogle Scholar
  17. 17.
    JCS Joint Working Group. Guidelines for pharmaco therapy of atrial fibrillation (JCS 2013)-digest version. Circ J. 2014;78:1997–2021.CrossRefGoogle Scholar
  18. 18.
    EAFT (European Atrial Fibrillation Trial) Study Group. Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. Lancet. 1993;342:1255–62.Google Scholar
  19. 19.
    Gorter JW. Major bleeding during anticoagulation after cerebral ischemi: patterns and risk factors. Stroke Prevention In Reversible Ischemia Trial (SPIRIT). European Atrial Fibrillation Trial (EAFT) study groups. Neurology. 1999;53:1319–27.CrossRefPubMedGoogle Scholar
  20. 20.
    Lopes RD, Alexander JH, Al-Khatib SM, et al. Apixaban for reduction in stroke and other thromboembolic events in atrial fi brillation (ARISTOTLE) trial: design and rationale. Am Heart J. 2010;159:331–9.CrossRefPubMedGoogle Scholar
  21. 21.
    Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16:31–41.CrossRefPubMedGoogle Scholar
  22. 22.
    Hunt SA, Abraham WT, Chin MH, et al. Focused update in corporated into the ACC/AHA 2005 guidelines for the diagnosis and management of heart failure in adults: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guide lines. Circulation. 2009;119:e391–479.CrossRefPubMedGoogle Scholar
  23. 23.
    Fang MC, Go AS, Chang Y, et al. Warfarin discontinuation after starting warfarin for atrial fibrillation. Circ Cardiovasc Qual Outcomes. 2010;3:624–31.CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Sorensen SV, Dewilde S, Singer DE, et al. Cost-effectiveness of warfarin: trial versus “real-world” stroke prevention in atrial fibrillation. Am Heart J. 2009;157:1064–73.CrossRefPubMedGoogle Scholar
  25. 25.
    Gallego P, Roldan V, Marin F, et al. Cessation of oral anticoagulation in relation to mortality and the risk of thrombotic events in patients with atrial fibrillation. Thromb Haemost. 2013;110:1189–98.CrossRefPubMedGoogle Scholar
  26. 26.
    Nieuwlaat R, Capucci A, Lip GY, et al. Antithrombotic treatment in real-life atrial fibrillation patients: a report from the Euro Heart Survey on Atrial Fibrillation. Eur Heart J. 2006;27:3018–26.CrossRefPubMedGoogle Scholar
  27. 27.
    Banerjee A, Lane DA, Torp-Pedersen C, Lip GY. Net clinical benefiet of new oral anlticoagulants (dabigadran, rivaroxaban, apixaban) versus no treatment in a ‘real world’ AF population: a modelling analysis based on a nationwide cohort study. Thromb Hacmost. 2012;107:584–9.CrossRefGoogle Scholar
  28. 28.
    Research Group for Antiarrhythmic Drug Therapy. Survey of atrial fibrillation and thromboembolism in the elderly: A multicenter coop- erative study. J Cardiol. 1999;33:27–35.Google Scholar
  29. 29.
    Cairns JA. Atrial fibrillation: Antithrombotic therapy. In: Yusuf S, Cairns JA, Camm AJ, Fallen EL, Gersh BJ, editors. Evidence-based cardiology. London: BMJ Books; 1998. p. 544–52.Google Scholar
  30. 30.
    Yasaka M, Minematsu K, Yamaguchi T. Optimal intensity of inter- national normalized ratio in warfarin therapy for secondary prevention of stroke in patients with non-valvular atrial fibrillation. Intern Med. 2001;40:1183–8.CrossRefPubMedGoogle Scholar
  31. 31.
    McCrory DC, Matchar DB, Samsa G, Sanders LL, Pritchett ELC. Physician attitudes about anticoagulation for nonvalvular atrial fibril- lation in the elderly. Arch Intern Med. 1995;155:277–81.CrossRefPubMedGoogle Scholar
  32. 32.
    Hylek EM, Go AS, Chang Y, et al. Effect of intensity of oral antico- agulation on stroke severity and mortality in atrial fibrillation. N Engl J Med. 2003;349:1019–26.CrossRefPubMedGoogle Scholar
  33. 33.
    Hylek EM, Singer DE. Risk factors for intracranial hemorrhage in outpatients taking warfarin. Ann Intern Med. 1994;120:897–902.CrossRefPubMedGoogle Scholar
  34. 34.
    Smith NL, Psaty BM, Furberg CD, White R, Lima JA, Newman AB, et al. Temporal trends in the use of anticoagulants among older adults with atrial fibrillation. Arch Intern Med. 1999;159:1574–8.CrossRefPubMedGoogle Scholar
  35. 35.
    Bradley BC, Perdue KS, Tisdel KA, Gilligan DM. Frequency of anticoagulation for atrial fibrillation and reasons for its non-use at a veterans affairs medical center. Am J Cardiol. 2000;85:568–72.CrossRefPubMedGoogle Scholar
  36. 36.
    Glazer NL, Dublin S, Smith NL, et al. Newly detected atrial fibrillation and compliance with antithrombotic guidelines. Arch Intern Med. 2007;167:246–52.CrossRefPubMedGoogle Scholar
  37. 37.
    Reynolds MR, Shah J, Essebag V, et al. Patterns and predictors of warfarin use in patients with new-onset atrial fibrillation from the FRACTAL Registry. Am J Cardiol. 2006;97:538–43.CrossRefPubMedGoogle Scholar
  38. 38.
    Gattellari M, Worthington J, Zwar N, et al. Barriers to the use of anticoagulation for nonvalvular atrial fibrillation: a representative survey of Australian family physicians. Stroke. 2008; 39: 227-230.Google Scholar
  39. 39.
    Anderson N, Fuller R, Dudley N. ‘Rules of thumb’ or reflective practice? Understanding senior physicians’ decision-making about antithrombotic usage in atrial fibrillation. QJM. 2007;100:263–9.CrossRefPubMedGoogle Scholar
  40. 40.
    Hughes M, Lip GY. Risk factors for anticoagulation-related bleeding complications in patients with atrial fibrillation: A systematic review. QJM. 2007;100:599–607.CrossRefPubMedGoogle Scholar
  41. 41.
    McNamara RL, Tamariz LJ, Segal JB, et al. Management of atrial fibrillation: Review of the evidence for the role of pharmacologic therapy, electrical cardioversion, and echocardiography. Ann Intern Med. 2003;139:1018–33.CrossRefPubMedGoogle Scholar
  42. 42.
    van Walraven C, Hart RG, Connolly S, et al. Effect of age on stroke prevention therapy in patients with atrial fibrillation. The Atrial Fibrillation Investigators. Stroke. 2009;40:1410–6.PubMedGoogle Scholar
  43. 43.
    Tanaka H, Hayashi M, Date C, Imai K, Asada M, Shoji H, et al. Epidemiologic studies of stroke in Shibata, a Japanese provincial city: Preliminary report on risk factors for cerebral infarction. Stroke. 1985;16:773–80.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media Singapore 2017

Authors and Affiliations

  1. 1.Department of Neurosurgery and Stroke CenterShinko Memorial HospitalKobe-cityJapan

Personalised recommendations